June 6, 2017 8:11am

 

… Some of the oversold are uttering an appeal while overbought are being lured to the rocks

Like Odysseus,  I’m confident I can listen to the Sirens and continue to write about it.

 

Pre-open indication:  eleven (11), 8 BUYS and 3 SELLS

 

Lower open expected

 

Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.

 

Are you reading; if not – you’re missing the facts in evidence that reflect reality and veracity? 

 

 


 

I know what a company is supposed to look like, be like, and smell like to succeed!

 

 

Dow futures are DOWN -0.23% and NASDAQ futures are DOWN -0.22%

 

 

U.S. stock index futures pointed to a lower open on Tuesday morning as traders reacted to escalating tensions in the Middle East and awaited the testimony of former FBI Director, James Comey.

European markets moved lower amid a political rift between Qatar and several other Arab countries and as investors took a cautious approach ahead of a general election in the U.K. and a European Central Bank (ECB) meeting.

Asian markets traded narrowly mixed, following the lower close on Wall Street and as markets digested the impact of diplomatic tensions between Qatar and other Middle Eastern nations.

 

Data docket: Job Openings and Labor Turnover Survey (JOLTS) data for April will be released at approximately 10 a.m. ET. The U.S. quarterly financial report for the first three months of the year is also due at around the same time.

 

 

The cell therapy sector closed NEGATIVE on Monday, POSITIVE on Friday and Thursday, NEGATIVE on Wednesday and last Tuesday.

The cell therapy sector’s record after the last 5 days (of 43 covered companies):

·         Monday closed NEGATIVE with 30 decliners, 10 advancers and 3 flats;

·         Friday closed POSITIVE with 11 decliners, 31 advancers and 1 flat;

·         Thursday closed POSITIVE with 10 decliners, 29 advancers and 4 flats;

·         Wednesday closed NEGATIVE with 24 decliners, 14 advancers and 5 flats;

·         Last Tuesday closed NEGATIVE with 29 decliners, 10 advancers and 4 flat;

 

 

Remembering Monday’s closing bell newsletter, “Even ASCO can’t shake negative sentiment. So, what will?  Pricing in the probability of adverse performance risks … it’s already there!”

As much as I see an upside for some, today gives me the heebie jeepbies !

Today will see lower volume … and a cautious buying environment and … more speculative selling

 

There are also jitters over three events on Thursday: the U.K. election, a European Central Bank announcement, and Comey’s testimony before the Senate panel, which is investigating Russian efforts to interfere in last year’s presidential race.

Geopolitical concerns have caused many to hedge outcomes, flee to safer havens and curb risk appetites!

 

 

What did I see on Monday, the DOW closed DOWN -0.10% (-22.25) as the NASDAQ also closed DOWN -0.16% (-10.11) … The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 9.8… sideways from Friday’s 9.8.

The count: look at the differences in the spreads …

•   Monday’s decliners ranged from -0.16% <CLLS> to -10.74% <JUNO> in 30 equities;

•   Monday’s gainers ranged from +0.68% (+$0.01) <ATHX> to +8.50% <BLUE> in 10 equities;

 

 

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades? 

Watch list:

  • The iShares Nasdaq Biotechnology (IBB) closed down -0.55% on Monday, and is NOT indicating in Tuesday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) closed Monday down -0.62% and is NOT indicating in Tuesday pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) closed down -0.28% Monday, and is NOT indicating in Tuesday’s pre-open;
  • The iShares Russell 2000 (IWM) closed down -0.62% on Monday, and is indicating a NEGATIVE -0.53% in Tuesday’s pre-open

 

 

Companies in my headlights:

All I see is momentum, no solid news and more speculation …

Aduro Biotech (ADRO) closed up +$0.15 to $10.30. June started at $9.90 while May finished at $10.00 with a high of $10.20 and a low of $9.65 having started at $9.70  the aftermarket is a negative -$0.05 or -0.48% - SELL;

Applied Genetic Technologies (AGTC) closed down -$0.275 to $4.825. The aftermarket indication is +$0.025 or +0.52% - BUY;

Athersys (ATHX) closed up +$0.01 to $1.49. The aftermarket indication is a negative -$0.005 or -0.33% - SELL;

Bellicum Pharmaceutics (BLCM) closed down -$0.28 to $10.71 after Friday’s $10.99 (+$0.06). The aftermarket indication was a positive +$0.63 or +5.88%. One reason, the initial – ASCO - Maintaining BUY;

bluebird bio (BLUE) closed up +$7.15 to $81.30 following Friday’s $85.15 (+$4.95). The aftermarket indication was +$0.40 or +0.44% - Maintaining BUY;

Cytori (CYTX) closed UP +$0.07 to $1.10. The aftermarket indication is a positive +$0.04 or +3.7% - BUY;

Juno Therapeutics (JUNO) closed down -$2.81 to $23.40 following Friday’s $26.21(+$1.71). The aftermarket indication is a positive +$0.62 or +2.67%. One reason – toxicity data was troubling– Maintaining BUY;

Kite Therapeutics (KITE) closed down -$1.88 to $73.61 following Friday’s $75.49 (+$0.83). The aftermarket indication is a positive +$0.06 or +0.08% - Maintaining BUY;

Sangamo Therapeutics (SGMO) closed flat at $7.20 following Friday’s $7.20 (+$0.20). The aftermarket indication was a negative -$0.15 or -2.08% - BUY to SELL;

Stemline (STML) closed down -$0.30 to $7.65. The aftermarket indication is a positive +$0.1.00 or +12.99% - BUY;

Verastem (VSTM) closed down -$0.04 to $2.15. The aftermarket indication is a positive +$0.12 or +5.48% - BUY;

 

 

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.